Source: Health Products Regulatory Authority (ZA) Publisher: Ranbaxy Pharmaceuticals (Pty) Ltd, 14 Lautre Road, Stormill, Ext 1, Roodepoort, 1724, South Africa
DEXISUN Concentrated solution for intravenous infusion.
| Pharmaceutical Form |
|---|
|
A clear, colourless solution, free from visible extraneous matter. |
Each 1 ml of sterile solution contains dexmedetomidine hydrochloride equivalent to 100 micrograms dexmedetomidine.
Contains sodium chloride (9,0 mg/ml).
For full list of excipients, see section 6.1
Sugar free.
| Active Ingredient | Description | |
|---|---|---|
| Dexmedetomidine |
Dexmedetomidine is a selective alpha-2 receptor agonist with a broad range of pharmacological properties. It has a sympatholytic effect through decrease of the release of noradrenaline in sympathetic nerve endings. The sedative effects are mediated through decreased firing of locus coeruleus, the predominant noradrenergic nucleus, situated in the brainstem. |
| List of Excipients |
|---|
|
Sodium chloride |
DEXISUN is packed in a 2 ml tubular, USP type 1 flint glass vial, with a 13 mm Teflon coated grey rubber stopper and a 13 mm pink aluminium flip-off seal, in a outer carton. Each carton contains 1 or 5 vials.
Ranbaxy Pharmaceuticals (Pty) Ltd, 14 Lautre Road, Stormill, Ext 1, Roodepoort, 1724, South Africa
54/2.9/0218
21 June 2022
| Drug | Countries | |
|---|---|---|
| DEXISUN | South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
